The most effective treatment approach for brain metastases in patients with non-small cell
lung cancer (NSCLC) and activating epidermal growth factor receptor (EGFR) mutations is a …

Non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR)
mutations commonly present brain metastases (BM) at the time of NSCLC diagnosis or …

Purpose Brain metastasis (BM) is a leading cause of death from non–small-cell lung cancer
(NSCLC). Reasoning that activation of the epidermal growth factor receptor (EGFR) …

The incidence of brain metastasis (BM) is high in patients with non-small-cell lung cancer.
Available standard therapeutic options, such as whole-brain radiation therapy and systemic …

Purpose/Objectives Radiation therapy (RT) is the principal modality in the treatment of
patients with brain metastases (BM). However, given the activity of EGFR tyrosine kinase …

Sequencing of the epidermal growth factor receptor (EGFR) gene to identify mutations in
lung adenocarcinomas is routine in clinical practice. The use of tyrosine kinase inhibitors …

Background/Aim: The optimal treatment strategy for epidermal growth factor receptor (EGFR)-
mutant non-small cell lung cancer (NSCLC) patients with brain metastasis (BM) has not yet …

Brain metastasis is a serious complication of non-small cell lung cancer (NSCLC) affecting
up to 40% of NSCLC patients. A subset of NSCLC tumors has mutations in the epidermal …

Epidermal growth factor receptor (EGFR) mutations are present in 20–40% of non-small cell
lung cancers (NSCLCs). Brain metastasis (BM) is more common in EGFR-mutated NSCLC …

The growth of genotype‐directed targeted therapies, such as inhibitors of the epidermal
growth factor receptor (EGFR), has revolutionized treatment for some patients with …